ESMO 2019—personal non-small lung cancer highlights

• DOI: 10.1007/s12254-020-00589-x
• Publication Date: 2020-03-20T17:05:51Z
• Authors: Lena Horvath; Andreas Pircher
• Keywords: Osimertinib; Risk Stratification; Targeted Therapy

Summary This article intends to summarize personal non-small cell lung cancer (NSCLC) highlights of the ESMO 2019 meeting. Again, immunotherapy in first-line setting wildtype NSCLC was a major aspect and search optimal biomarker for therapy stratification continues. Moreover, important data on use osimertinib, third-generation epidermal growth factor receptor (EGFR) inhibitor EGFR-mutated were presented, emerging as preferred therapeutic strategy these patients. The ideal treatment sequence, however, remains discussed controversially. rare genetic alterations another topic, covering updated effective NTRK ROS1 inhibition. In conclusion, fueled community with inspiring new data, contributing more individualized, hopefully improved continuing decrease mortality.